Proteomic pattern analysis discriminates among multiple sclerosis-related disorders

Annals of Neurology

Volumn 71, Issue 5, 2012, Pages 614-623

  Komori, Mika ^a   Matsuyama, Yumiko ^b   Nirasawa, Takashi ^b   Thiele, Herbert ^b   Becker, Michael ^b   Alexandrov, Theodore ^c   Saida, Takahiko ^d   Tanaka, Masami ^d   Matsuo, Hidenori ^e   Tomimoto, Hidekazu ^a   Takahashi, Ryosuke ^a   Tashiro, Kei ^f   Ikegawa, Masaya ^f   Kondo, Takayuki ^g  

^a KYOTO UNIVERSITY   (Japan)

^b BRUKER DALTONIK GMBH   (Germany)

^c UNIVERSITY OF BREMEN   (Germany)

^d UTANO NATIONAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g Kitano Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4;

ADOLESCENT; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; SUPPORT VECTOR MACHINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROMYELITIS OPTICA; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84860183712     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22633     Document Type: Article

References (35)

1. Sospedra M, Martin R,. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
3. Tanaka M, Tanaka K, Komori M,. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 2009; 62: 167-170.
4. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
7. Tanaka M, Tanaka K, Komori M, Saida T,. Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J Neurol Neurosurg Psychiatry 2007; 78: 990-992.
8. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964-968.
9. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009; 66: 1134-1138.
10. Cabrera-Gomez JA, Bonnan M, Gonzalez-Quevedo A, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler 2009; 15: 828-833.
11. Miller DH, Leary SM,. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6: 903-912.
12. Koch M, Kingwell E, Rieckmann P, Tremlett H,. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73: 1996-2002.
13. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
14. Hammack BN, Fung KY, Hunsucker SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10: 245-260.
15. Noben JP, Dumont D, Kwasnikowska N, et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2006; 5: 1647-1657.
16. Stoop MP, Dekker LJ, Titulaer MK, et al. Quantitative matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis- related proteins. J Proteome Res 2009; 8: 1404-1414.
17. Dumont D, Noben JP, Raus J, et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004; 4: 2117-2124.
18. Lehmensiek V, Sussmuth SD, Tauscher G, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13: 840-849.
19. D'Aguanno S, Barassi A, Lupisella S, et al. Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. J Neuroimmunol 2008; 193: 156-160.
20. Irani DN, Anderson C, Gundry R, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2006; 59: 237-247.
21. Ottervald J, Franzén B, Nilsson K, et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010; 73: 1117-1132.
22. Comabella M, Fernandez M, Martin R,. et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093.
23. Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009; 80: 575-577.
24. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006; 66: 1218-1222.
25. Huang JT, Leweke FM, Oxley D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 2006; 3: e428.
26. Sekiyama E, Matsuyama Y, Higo D, et al. Applying magnetic bead separation/MALDI-TOF mass spectrometry to human tear fluid proteome analysis. J Proteomics Bioinform 2008; 1: 368-373.
27. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-846.
28. Tanaka K, Tani T, Tanaka M, et al. Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler 2007; 13: 850-855.
29. Ivosev G, Burton L, Bonner R,. Dimensionality reduction and visualization in principal component analysis. Anal Chem 2008; 80: 4933-4944.
30. Alexandrov T, Decker J, Mertens B, et al. Biomarker discovery in MALDI-TOF serum protein profiles using discrete wavelet transformation. Bioinformatics 2009; 25: 643-649.
31. Freiwald A, Sauer S,. Phylogenetic classification and identification of bacteria by mass spectrometry. Nat Protoc 2009; 4: 732-742.
32. Nagy E, Maier T, Urban E, et al. Species identification of clinical isolates of Bacteroides by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2009; 15: 796-802.
33. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-1913.
34. Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 2009; 132: 1190-1199.
35. Appel SH, Beers DR, Henkel JS,. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 2010; 31: 7-17.